In 2014, the American Academy of Pediatrics released a statement regarding off-label use of pharmaceuticals in children.
By default use of non-approved drugs is common in obstetrics as, by 2010, during almost five decades of activity the Food and Drug Administration (FDA) had approved only two drugs for obstetrical indications, namely oxytocin and dinoprostone [REF].